30S Stock Chart & Stats
€1.93
>-€0.01(-0.49%)
At close: 4:00 PM EST
€1.93
>-€0.01(-0.49%)
Day’s Range― - ―
52-Week Range€0.70 - €2.58
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€159.92M
Enterprise Value€1.24B
Total Cash (Recent Filing)€531.98M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)8.1
Beta-0.02
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.59
Shares Outstanding138,030,140
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)4.30
Price to Sales (P/S)6.29
P/FCF Ratio13.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€1.03M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt across 2025 and TTM materially reduces financial leverage and bankruptcy risk, giving management durable optionality to fund development, delay dilutive financing, or pursue partnerships. This structural strength supports resilience through biotech development cycles.
Positive Operating And Free Cash FlowSustained positive operating and free cash flow indicates earnings are largely cash-backed, improving funding capacity for R&D and reducing reliance on equity markets. Over months, cash-backed profitability strengthens runway and strategic negotiating leverage with partners.
Very High TTM Profitability MarginsExceptionally high gross and operating margins signal efficient cost structure or high pricing power in current revenue base, enabling strong internal cash generation. If maintained, these margins enhance ability to self-fund development and deliver durable returns on incremental revenue.
Bears Say
Revenue Volatility And Recent DeclineLarge swings in top-line create unpredictability in funding and planning for a development-stage biotech. Dependence on lumpy milestone or licensing revenue undermines sustainable growth and complicates multi-quarter cash forecasting, increasing financing and execution risk.
Historical Balance-sheet InstabilityA prior episode of negative equity and heavy leverage indicates material past financial stress; although currently debt-free, the history shows balance-sheet metrics can deteriorate. This raises the likelihood that funding cycles or setbacks could force dilutive raises again.
Negative Free Cash Flow Growth TrendDespite positive absolute FCF now, declining free cash flow growth and recent multi-year cash burn suggest fragile cash durability. Continued negative growth would erode runway and may compel external financing, reducing long-term financial flexibility for program advancement.
Saniona AB News
30S FAQ
What was Saniona AB’s price range in the past 12 months?
Saniona AB lowest stock price was €0.70 and its highest was €2.58 in the past 12 months.
What is Saniona AB’s market cap?
Saniona AB’s market cap is €159.92M.
When is Saniona AB’s upcoming earnings report date?
Saniona AB’s upcoming earnings report date is Aug 27, 2026 which is in 31 days.
How were Saniona AB’s earnings last quarter?
Saniona AB released its earnings results on May 26, 2026. The company reported -€0.031 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.031.
Is Saniona AB overvalued?
According to Wall Street analysts Saniona AB’s price is currently Overvalued.
Does Saniona AB pay dividends?
Saniona AB does not currently pay dividends.
What is Saniona AB’s EPS estimate?
Saniona AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Saniona AB have?
Saniona AB has 138,030,140 shares outstanding.
What happened to Saniona AB’s price movement after its last earnings report?
Saniona AB reported an EPS of -€0.031 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.117%.
Which hedge fund is a major shareholder of Saniona AB?
Currently, no hedge funds are holding shares in DE:30S
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Saniona AB
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disorders. The company's pipeline features Tesofensine, a monoamine reuptake inhibitor, and Tesomet, a fixed-dose combination of tesofensine and metoprolol, which has advanced through Phase 2 clinical trials for Prader-Willi Syndrome and hypothalamic obesity. Additionally, Saniona is progressing SAN711, currently in Phase 1 for rare neuropathic conditions, and SAN903, an early-stage candidate in preclinical development for rare inflammatory, fibrotic, and hematological ailments. Saniona also engages in various strategic collaborations, including research and partnership agreements with Boehringer Ingelheim International GmbH, a licensing deal with Productos Medix, S.A. de C.V., and both research services and collaboration agreements with Cephagenix ApS.
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Xbrane Biopharma AB
―
Xspray Pharma AB
―
Cantargia AB
―